Rosamund Wilson

1.6k citations

31 papers · 976 indexed · 1 hit paper · h-index 16

Co-authors: Clive Weston A. Hutchison Nathalie Goemans M. van den Hauwe Gunnar Buyse John B. Copley G. Campion Raymond Pratt
Topics: Parathyroid Disorders and Treatments (9 papers)Magnesium in Health and Disease (8 papers)Muscle Physiology and Disorders (5 papers)
Cited by: Nephrology Immunology and Allergy Emergency Medicine
Journals: JAMA Circulation Journal of Clinical Oncology
Partner nations: United Kingdom United States Germany

In The Last Decade

Rosamund Wilson

30 papers receiving 933 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels

2022 209 citations Steven E. Nissen, Daniel I. Swerdlow et al. profile →

Peers

Countries citing papers authored by Rosamund Wilson

Since Specialization

Citations

This map shows the geographic impact of Rosamund Wilson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rosamund Wilson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rosamund Wilson more than expected).

Fields of papers citing papers by Rosamund Wilson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rosamund Wilson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rosamund Wilson. The network helps show where Rosamund Wilson may publish in the future.

Co-authorship network of co-authors of Rosamund Wilson

This figure shows the co-authorship network connecting the top 25 collaborators of Rosamund Wilson. A scholar is included among the top collaborators of Rosamund Wilson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rosamund Wilson. Rosamund Wilson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial 2023 ·British Journal of Dermatology ·Stephan Weidinger,Thomas Bieber,Michael J. Cork,Adam Reich,Rosamund Wilson,Sonia Quaratino,Marisa Stebegg,(unknown),(unknown),John T. O’Malley,(unknown)	61
2	41343 Safety of Amlitelimab in a Phase 2a Clinical Trial of Patients With Moderate-to-Severe Atopic Dermatitis 2023 ·Journal of the American Academy of Dermatology ·Stephan Weidinger,Michael J. Cork,Adam Reich,Thomas Bieber,(unknown),Sonia Quaratino,Rosamund Wilson,(unknown)	1
3	Abstract 10469: Time Averaged Lipoprotein(a) Reduction With Sln360, a Novel Sirna Targeting Lp(a,) in Healthy Adults With Elevated Lp(a) 2022 ·Circulation ·Curtis Rambaran,Rosamund Wilson,Daniel I. Swerdlow,G. Campion,(unknown),Steven E. Nissen	2
4	A phase 1/2 open-label study of KY1044, an anti-ICOS antibody with dual mechanism of action, as single agent and in combination with atezolizumab, in adult patients with advanced malignancies. 2021 ·Journal of Clinical Oncology ·Manish R. Patel,Aung Naing,Howard A. Burris,Chia‐Chi Lin,Giuseppe Curigliano,Fiona Thistlethwaite,Anna Minchom,Paolo A. Ascierto,Filippo de Braud,Michael Cecchini,(unknown),Richard C.A. Sainson,Rosamund Wilson,Sonia Quaratino	14
5	Placebo‐controlled Phase 2 Trial of Drisapersen for Duchenne Muscular Dystrophy 2018 ·Annals of Clinical and Translational Neurology ·Craig M. McDonald,Brenda Wong,Kevin M. Flanigan,Rosamund Wilson,S. de Kimpe,Afrodite Lourbakos,Zhengning Lin,(unknown),(unknown)	29
6	A new lipid formulation of low dose ibuprofen shows non-inferiority to high dose standard ibuprofen: the FLARE study (flaring arthralgia relief evaluation in episodic flaring knee pain) – a randomised double-blind study 2017 ·Osteoarthritis and Cartilage ·Sita Bierma‐Zeinstra,J. O. Brew,(unknown),Rosamund Wilson,(unknown),Philip G. Conaghan	7
7	Elemental calcium intake associated with calcium acetate/calcium carbonate in the treatment of hyperphosphatemia 2017 ·Drugs in Context ·Rosamund Wilson,J. Brian Copley	2
8	Comparison of ambulatory capacity and disease progression of Duchenne muscular dystrophy subjects enrolled in the drisapersen DMD114673 study with a matched natural history cohort of subjects on daily corticosteroids 2016 ·Neuromuscular Disorders ·Nathalie Goemans,M. Tulinius,Anna‐Karin Kroksmark,Rosamund Wilson,M. van den Hauwe,(unknown)	13
9	Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study 2016 ·PLoS ONE ·Nathalie Goemans,M. Tulinius,M. van den Hauwe,Anna‐Karin Kroksmark,Gunnar Buyse,Rosamund Wilson,Judith C. van Deutekom,Sjef J. de Kimpe,Afrodite Lourbakos,(unknown)	66
10	Real-World Dose-Relativity, Tablet Burden, and Cost Comparison of Conversion Between Sevelamer Hydrochloride/Carbonate and Lanthanum Carbonate Monotherapies 2014 ·Clinical Therapeutics ·Michael W. Keith,Scott Sibbel,J. Brian Copley,Rosamund Wilson,Steven M. Brunelli	3
11	Cost-Minimization Analysis of Lanthanum Carbonate Versus Sevelamer Hydrochloride in US Patients With End-stage Renal Disease 2014 ·Clinical Therapeutics ·Michael W. Keith,Rosamund Wilson,Peter Preston,J. Brian Copley	15
12	Ambulatory capacity and disease progression as measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids 2013 ·Neuromuscular Disorders ·Nathalie Goemans,M. van den Hauwe,Rosamund Wilson,(unknown),Katrijn Klingels,Gunnar Buyse	53
13	Dose relativity of sevelamer hydrochloride and lanthanum carbonate under real-world conditions: Implications for management of patients with end-stage renal disease and hyperphosphatemia 2013 ·Value in Health ·J. Brian Copley,Rosamund Wilson,Michael W. Keith	0
14	The Real-World Dose-Relativity of Sevelamer Hydrochloride and Lanthanum Carbonate Monotherapy in Patients with End-Stage Renal Disease 2013 ·Advances in Therapy ·Rosamund Wilson,Michael W. Keith,Peter Preston,J. Brian Copley	11
15	Lanthanum carbonate versus placebo for management of hyperphosphatemia in patients undergoing peritoneal dialysis: a subgroup analysis of a phase 2 randomized controlled study of dialysis patients 2013 ·BMC Nephrology ·A. Hutchison,(unknown),J. Brian Copley,Lynne Poole,Rosamund Wilson	15
16	T.I.2 Exon skipping and PRO044 in Duchenne muscular dystrophy: Extending the program 2013 ·Neuromuscular Disorders ·Alessandra Ferlini,(unknown),M. Tulinius,E. Niks,(unknown),Allison Morgan,Afrodite Lourbakos,Sjef J. de Kimpe,Rosamund Wilson,Annarita Armaroli,J. van Deutekom,G. Campion	2
17	Preclinical development of CAT‐354, an IL‐13 neutralizing antibody, for the treatment of severe uncontrolled asthma 2011 ·British Journal of Pharmacology ·Richard May,(unknown),E. Suzanne Cohen,(unknown),Fiona C. Dempsey,(unknown),(unknown),D Corkill,(unknown),(unknown),(unknown),Frank Köentgen,(unknown),Rosamund Wilson,(unknown),(unknown),(unknown)	83
18	An open‐label, single‐dose bioavailability study of the pharmacokinetics of CAT‐354 after subcutaneous and intravenous administration in healthy males 2010 ·British Journal of Clinical Pharmacology ·Chad K. Oh,Raffaella Faggioni,Feng Jin,Lorin Roskos,Bing Wang,Claire Birrell,Rosamund Wilson,Néstor A. Molfino	53
19	Predicting survival from out-of-hospital cardiac arrest: a multivariate analysis 1997 ·Resuscitation ·Clive Weston,Rosamund Wilson,(unknown)	75
20	Outcome of out-of-hospital cardiorespiratory arrest in South Glamorgan 1997 ·Resuscitation ·Clive Weston,(unknown),Rosamund Wilson	59

About Rosamund Wilson

Rosamund Wilson is a scholar working on Nephrology, Nutrition and Dietetics and Dermatology, having authored 31 papers that have together received 976 indexed citations. Recurring topics across this work include Parathyroid Disorders and Treatments (9 papers), Magnesium in Health and Disease (8 papers) and Muscle Physiology and Disorders (5 papers). The work is most often cited by research in Nephrology (128 citations), Immunology and Allergy (96 citations) and Emergency Medicine (130 citations). Rosamund Wilson has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include Clive Weston, A. Hutchison, Nathalie Goemans, M. van den Hauwe, Gunnar Buyse, John B. Copley, G. Campion, Raymond Pratt, Steven E. Nissen and Traci Turner. Their work appears in journals such as JAMA, Circulation and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact